Akari Therapeutics plc, a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, released its financial results for the first quarter of 2025. The company reported a net loss from operations of approximately $3.7 million for the three months ended March 31, 2025, compared to a net loss of $5.6 million for the same period in 2024. Research and development expenses decreased to $0.8 million from $2.3 million in the first quarter of 2024, primarily due to the suspension of the HSCT-TMA clinical stage program with nomacopan in May 2024. General and administrative expenses were also reduced to $2.7 million from $3.7 million in the prior year, attributed to decreases in legal and professional fees and a reduction in directors' and officers' insurance costs. As of March 31, 2025, Akari Therapeutics had cash reserves of approximately $2.6 million. The net proceeds from the company's March 2025 offering were approximately $6.0 million, with $4.0 million received in April 2025. The company continues to focus on becoming a key player in the ADC space, advancing its ADC platform with immuno-oncology payloads, and developing its lead asset AKTX-101, an ADC targeting Trop2. The appointment of Mark Kubik as Head of Business Development, Oncology, is expected to strengthen the company's position in the Antibody Drug Conjugate space.